Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
subcutaneous
Biotech
Lundbeck’s preventative migraine IV sees success in ph. 2
Based on the findings, the Danish pharma plans on discussing phase 3 design options with regulators.
Gabrielle Masson
Feb 12, 2026 1:25pm
Fierce Pharma
Halozyme CEO targets new deals as IRA uncertainty subsides
Oct 14, 2025 9:40am
Fierce Pharma
Halozyme buys Elektrofi for up to $900M
Oct 1, 2025 2:36pm
Astellas taps ReForm to improve clinical-phase biologics
Mar 5, 2019 9:39am
Bristol-Myers pays Halozyme $105M to access I-O delivery tech
Sep 14, 2017 6:59am
Omeros defends drug data, vows to unmask short seller
Aug 24, 2017 9:52am
